Abeona Therapeutics (NASDAQ:ABEO) Upgraded to “Hold” at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Abeona Therapeutics in a research note on Monday, November 25th.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $5.57 on Tuesday. The company has a market capitalization of $242.13 million, a PE ratio of -2.07 and a beta of 1.44. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company’s 50 day moving average price is $6.02 and its 200 day moving average price is $5.59. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $9.01.

Hedge Funds Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics during the 3rd quarter worth $84,000. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics during the 3rd quarter worth $151,000. XTX Topco Ltd bought a new stake in Abeona Therapeutics during the third quarter valued at about $160,000. JPMorgan Chase & Co. grew its position in shares of Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after purchasing an additional 28,606 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 2,434 shares during the period. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.